PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer

Anneke Westermann,Petronella Ottevanger,An Reyners,Judith R Kroep,Martijn G H Van Oijen,Roy Lalisang,Petronella O Witteveen

doi:10.1136/ijgc-2023-004781

PAZEC: a Dutch Gynaecological Oncology Group open-label, multicenter, phase II study of pazopanib in metastatic and locally advanced hormone-resistant endometrial cancer

Anneke Westermann, Petronella Ottevanger + Show 5 more

https://doi.org/10.1136/ijgc-2023-004781

Copy DOI

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Publication Date: Jan 6, 2024

Affiliation: Amsterdam University Medical Centers, University Medical Center Groningen, Leiden University Medical Center, Cancer Center Amsterdam, Maastricht University, University Medical Center Utrecht

#Advanced Endometrial Cancer #Severe Gastrointestinal Toxicity + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

ObjectiveThere is a continued need for improvement of second-line systemic treatment for metastatic and/or recurrent endometrial cancer.MethodsIn this phase II, open-label study, eligible patients had histologically or cytologically confirmed endometrial...

Full Text